Sensorion Stock

Sensorion Equity

The The Equity of Sensorion (ALSEN.PA) as of Aug 1, 2026 is 44.48 M EUR. In the previous year, The Equity was 72.14 M EUR — a change of -38.34% (lower).

Equity

44.48 MEUR

YoY

-38.34%

Last updated:

In 2026, Sensorion's equity was 44.48 M EUR, a -38.34% increase from the 72.14 M EUR equity in the previous year.

Access this data via the Eulerpool API

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Sensorion's Equity

Sensorion's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sensorion's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sensorion's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sensorion's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sensorion’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sensorion stock

The Equity of Sensorion is 44.48 M EUR in 2026.

Access this data via the Eulerpool API

Balance Sheet — Sensorion

All Key Metrics — Sensorion